Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Background Angiotensin-converting enzyme inhibitors have been used as the standard of care for the treatment of diabetic nephropathy. Recently, dapagliflozin has been shown to reduce diabetic nephropathy when added to the standard of care.Objective The objective of this study was to determine the cost effectiveness of dapagliflozin added to the standard of care in diabetic nephropathy in the United States of America (USA).Methods A Markov model was developed to determine the cost-effectiveness outcomes from the Medicare/Medicaid health coverage perspective. Model inputs were derived from the literature. The primary outcomes were total costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio. Deterministic and probabilistic sensitivity analyses were performed to determine the robustness of our results. A willingness-to-pay threshold of $100,000 per QALY was applied, which is based on previous studies.Results Dapagliflozin yielded a lifetime QALY of 2.8. The discounted QALY associated with the standard of care was 2.6. The standard of care was the less costly treatment with a lifetime cost of $106,150.25 as compared with dapagliflozin, which costs $110,689.25. Dapagliflozin demonstrated an incremental cost-effectiveness ratio of $21,141.51 per additional QALY. The most influential parameters of the incremental cost-effectiveness ratio were the adverse drug reaction-related cost of the standard of care and dapagliflozin, the acquisition cost, and the adverse drug reaction-related cost of dapagliflozin. The effects and costs of the interventions were consistent between base-case analyses and the probabilistic model (incremental cost-effectiveness ratio: $19,023.35 [$13,637.8-$27,483.1]).Conclusions Dapagliflozin added to the standard of care was cost effective relative to the standard of care alone in the USA for patients with diabetic nephropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Avoiding or delaying costly kidney replacement therapy may make it cost-effective to implement the new therapies, [41][42][43] but more data are needed to support this possibility.”
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“Dapagliflozin is one of the SGLT2i that reduces the risk of kidney disease progression [12].”
BackgroundDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 1×
“Our finding is supported with another study in which dapagliflozin improved renal function and reduced the progression of kidney disease in patients with or without diabetes, which may result in better health outcome [76].”
ResultWolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069 · cited 12×
“Captopril is the only USA Food and Drug Administration-approved angiotensinconverting enzyme inhibitor to reduce proteinuria and to slow DN [8, 9].”
MethodInfluentialDiabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399 · cited 1×
“More recently, sodium-glucose cotransporter inhibitors (SGLT2i) were shown to reduce chronic kidney disease progression when added to the SoC [10].”
BackgroundUS Renal Data System 2020 annual data report: epidemiology of kidney disease in the United States
Johansen, K. L., Chertow, G. M., Foley, R. N., Gilbertson, D. T., Herzog, C. A., Ishani, A., Israni, A. K., Ku, E., Kurella Tamura, M., Li, S., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.01.002 · Cited by 724 · cited 1×
“The probabilities of patients undergoing dialysis and a transplant were sourced from the 2020 US renal data system annual report [23].”
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“use of SGLT2i imposes a higher risk of DKA in patients with precipitating factors due to glycosuria [78].”
BackgroundDiabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
Palmer, A. J., Roze, S., Valentine, W. J., Minshall, M. E., Foos, V., Lurati, F. M., Lammert, M., & Spinas, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x1980 · Cited by 526 · cited 2×
“The CORE Diabetes Model was based on a series of sub-models that simulate different complications of DM [17].”
MethodWyld, M., Morton, R. L., Hayen, A., Howard, K., & Webster, A. C. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001307 · Cited by 515
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000311 · Cited by 508 · cited 1×
“Sodium-glucose cotransporter inhibitors are a class of prescription medicines approved for use in adults with type 2 diabetes [11].”
United States Renal Data System (USRDS).
Agodoa, L. (2000) · PubMed · Cited by 490
Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019
Deng, Y., Li, N., Wu, Y., Wang, M., Yang, S., Zheng, Y., Deng, X., Xiang, D., Zhu, Y., Xu, P., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.672350 · Cited by 319
Diabetic nephropathy in type II diabetes
Ritz, E., & Stefanski, A. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90538-7 · Cited by 261
Cardiovascular Mortality in End-Stage Renal Disease
Collins, A. J. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200304000-00002 · Cited by 238 · cited 1×
“Cardiovascular complications account for more than 50% of kidney-related deaths [4].”
BackgroundDesai, D., Mehta, D., Mathias, P., Menon, G., & Schubart, U. K. (2018) · Diabetes Care · doi:10.2337/dc17-1379 · Cited by 206
Pollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C. D., Wheeler, D. C., Langkilde, A. M., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30086-5 · Cited by 205 · cited 3×
“The probabilities of drugrelated hypoglycemic events, amputations, fracture, volume depletion, urinary and genital tract infections, myocardial infarction, stroke, heart failure, and ketoacidosis were also included in the model [14].”
BackgroundResultInfluentialThe cost‐effectiveness of increasing kidney transplantation and home‐based dialysis
HOWARD, K., SALKELD, G., WHITE, S., MCDONALD, S., CHADBAN, S., CRAIG, J. C., & CASS, A. (2009) · Nephrology · doi:10.1111/j.1440-1797.2008.01073.x · Cited by 201
Mathiesen, E. R., Hommel, E., Hansen, H. P., Smidt, U. M., & Parving, H.-H. (1999) · BMJ · doi:10.1136/bmj.319.7201.24 · Cited by 192 · cited 1×
“Captopril is the only USA Food and Drug Administration-approved angiotensinconverting enzyme inhibitor to reduce proteinuria and to slow DN [8, 9].”
BackgroundHeerspink, H. J. L., Johnsson, E., Gause‐Nilsson, I., Cain, V. A., & Sjöström, C. D. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12654 · Cited by 191
Microalbuminuria in Type 2 Diabetes and Hypertension
Basi, S., Fesler, P., Mimran, A., & Lewis, J. B. (2008) · Diabetes Care · doi:10.2337/dc08-s249 · Cited by 188
The Clinical Course of Diabetic Nephropathy
Kussman, M. J. (1976) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1976.03270170027020 · Cited by 173 · cited 1×
“A lifetime time horizon was considered with a cycle duration of 1 year based on the transition time of each state [24].”
MethodEvans, M., Khunti, K., Mamdani, M., Galbo-Jørgensen, C. B., Gundgaard, J., Bøgelund, M., & Harris, S. (2013) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-11-90 · Cited by 166
McEwan, P. C., Darlington, O. T., McMurray, J. J. V., Jhund, P. S., Docherty, K. F., Böhm, M., Petrie, M. C., Bergenheim, K., & Qin, L. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1978 · Cited by 165
Characterisation and comparison of health-related quality of life for patients with renal failure
Lee, A. J., Morgan, C. L., Conway, P., & Currie, C. J. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65277 · Cited by 155
A Computer Simulation Model of Diabetes Progression, Quality of Life, and Cost
Zhou, H., Isaman, D. J. M., Messinger, S., Brown, M. B., Klein, R., Brandle, M., & Herman, W. H. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2856 · Cited by 121
Cost analysis of dialysis treatments for end-stage renal disease (ESRD).
Goeree, R. A., Jaime Mañalich, M., Grootendorst, P. V., Beecroft, M. L., & Churchill, D. N. (1995) · PubMed · Cited by 115
Hospitalizations for osteoporosis-related fractures: Economic costs and clinical outcomes
Weycker, D. A., Li, X., Barron, R., Bornheimer, R., & Chandler, D. (2016) · Bone Reports · doi:10.1016/j.bonr.2016.07.005 · Cited by 114
Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation
Kiberd, B. A., & Jindal, K. K. (1995) · BMJ · doi:10.1136/bmj.311.7020.1595 · Cited by 102
The health care costs of diabetic nephropathy in the United States and the United Kingdom
Gordois, A., Scuffham, P., Shearer, A. T., & Oglesby, A. K. (2004) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(03)00035-7 · Cited by 98 · cited 12×
“Captopril is the only USA Food and Drug Administration-approved angiotensinconverting enzyme inhibitor to reduce proteinuria and to slow DN [8, 9].”
BackgroundInfluentialPalmer, A. J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R., Gabriel, S., Carita, P., Rodby, R. A., de Zeeuw, D., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1897 · Cited by 93
Jesky, M. D., Dutton, M., Dasgupta, I., Yadav, P., Ng, K. P., Fenton, A., Kyte, D., Ferro, C. J., Calvert, M., Cockwell, P., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165675 · Cited by 92 · cited 1×
“The disutility associated with each DN stage was included for each transition state [46].”
BackgroundEconomic burden of osteoporotic fractures in US managed care enrollees
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.43156 · Cited by 90
Loss of health related quality of life following low-trauma fractures in the elderly
Tarride, J., Burke, N., Leslie, W. D., Morin, S. N., Adachi, J. D., Παπαϊωάννου, Α., Bessette, L., Brown, J. P., Pericleous, L., Muratov, S., et al. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0259-5 · Cited by 77
Harris, S., Mamdani, M., Galbo-Jørgensen, C. B., Bøgelund, M., Gundgaard, J., & Groleau, D. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.09.001 · Cited by 76
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease
Erickson, K. F., Japa, S., Owens, D. K., Chertow, G. M., Garber, A. M., & Goldhaber-Fiebert, J. D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.034 · Cited by 74
Hemodialysis for end-stage renal disease: A cost-effectiveness analysis of treatment options
Perez, J. G. G., Vale, L. D., Stearns, S. C., & Wordsworth, S. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s026646230505004x · Cited by 70
Peasgood, T., Brennan, A., Mansell, P., Elliott, J., Basarir, H., & Kruger, J. (2016) · Medical Decision Making · doi:10.1177/0272989x16658660 · Cited by 66
Krittayaphong, R., & Permsuwan, U. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.017 · Cited by 65
Pike, E., Hamidi, V., Ringerike, T., Wisløff, T. F., & Klemp, M. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2817w · Cited by 63
Trends in healthcare expenditure in United States adults with chronic kidney disease: 2002–2011
Ozieh, M. N., Bishu, K. G., Dismuke, C. E., & Egede, L. E. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2303-3 · Cited by 63
Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective
Ferguson, T. W., Tangri, N., Tan, Z., James, M. T., Lavallee, B., Chartrand, C. D., McLeod, L., Dart, A. B., Rigatto, C., & Komenda, P. V. J. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.022 · Cited by 62
The financial impact of immunosuppressant expenses on new kidney transplant recipients* ,†
Gordon, E. J., PROHASKA, T. R., & Sehgal, A. R. (2008) · Clinical Transplantation · doi:10.1111/j.1399-0012.2008.00869.x · Cited by 61 · cited 1×
“The average cost of immunosuppressants (antirejection therapy) was included according to the Kidney Disease Improving Global Outcomes recommendation [60].”
MethodParacha, N., Abdulla, A., & MacGilchrist, K. S. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-0994-8 · Cited by 61
Sugrue, D., Ward, T. T., Rai, S., McEwan, P. C., & van Haalen, H. G. M. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00835-z · Cited by 58
Boersma, C., Gansevoort, R. T., Pechlivanoglou, P., Visser, S. T., van Toly, F. F. J., den Berg, L. T. W. D. J., de Jong, P. E., & Postma, M. J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.013 · Cited by 56
Yang, F. B., Lau, T., & Luo, N. (2015) · Nephrology · doi:10.1111/nep.12668 · Cited by 56
A health economic analysis of clinical islet transplantation
Beckwith, J., Nyman, J. A., Flanagan, B., Schrover, R., & Schuurman, H. (2012) · Clinical Transplantation · doi:10.1111/j.1399-0012.2011.01411.x · Cited by 52
Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
Tisdale, R. L., Cusick, M. M., Aluri, K. Z., Handley, T. J., Joyner, A. K. C., Salomon, J. A., Chertow, G. M., Goldhaber‐Fiebert, J. D., & Owens, D. K. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07311-5 · Cited by 51 · cited 3×
“It also minimized the number of patients who require renal replacement therapy in patients with non-diabetes kidney disease [16].”
BackgroundMethodInfluentialCost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
Nguyen, E., Coleman, C. I., Nair, S., & Weeda, E. R. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.10.006 · Cited by 48 · cited 1×
“02) in the SoC could result in worsening of health outcomes of SoC [75, 77].”
BackgroundWu, B., Zhang, S., Lin, H., & Mou, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12653 · Cited by 40
Thokala, P., Kruger, J., Brennan, A., Basarir, H., Duenas, A., Pandor, A., Gillett, M., Elliott, J., & Heller, S. (2014) · Diabetic Medicine · doi:10.1111/dme.12371 · Cited by 39
Willis, M., Nilsson, A., Kellerborg, K., Ball, P., Roe, R., Traina, S., Beale, R., & Newell, I. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00968-x · Cited by 36 · cited 1×
“Another cost-utility study revealed that canagliflozin, a class of SGLT2i, was found to be cost effective attributing to high cost savings with low cardiovascular and renal complications [54].”
BackgroundDIALYSIS FOR END-STAGE RENAL DISEASE
Kirby, L., & Vale, L. D. (2001) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300105045 · Cited by 30
Grandy, S., Langkilde, A. M., Sugg, J. E., Parikh, S. J., & Sjöström, C. D. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12341 · Cited by 29 · cited 1×
“The utilities with each medication were extracted from studies that measured patients’ health-related quality of life using EQ-5D [44, 45].”
MethodLittlewood, K. J., Greiner, W., Baum, D., & Zöllner, Y. F. (2007) · BMC Nephrology · doi:10.1186/1471-2369-8-9 · Cited by 22
Okubo, R., Kondo, M., Hoshi, S., & Kunihiro, Y. (2015) · Sleep And Breathing · doi:10.1007/s11325-015-1134-x · Cited by 17
Requisite models for strategic commissioning: the example of type 1 diabetes
Airoldi, M., Bevan, G., Morton, A., Oliveira, M. D., & Smith, J. A. E. (2008) · Health Care Management Science · doi:10.1007/s10729-008-9056-9 · Cited by 15
Ishii, H., Nakajima, H., Kamei, N., Niiya, T., Hiyoshi, T., Hiramori, Y., Ohtsu, S., Noto, T., & Shimono, D. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00941-8 · Cited by 15 · cited 1×
“The utilities with each medication were extracted from studies that measured patients’ health-related quality of life using EQ-5D [44, 45].”
MethodLin, W.-Q., Cai, Z.-J., Chen, T., Liu, M.-B., Li, N., & Zheng, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.684960 · Cited by 14
Campbell, H. M., Boardman, K. D., Dodd, M. A., & Raisch, D. W. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k074 · Cited by 12
McEwan, P. C., Darlington, O. T., Wheeler, D. C., Heerspink, H. J. L., Bergenheim, K., & Sanchez, J. G. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.03.351 · Cited by 11
Amos, T. B., Montejano, L. B., Juneau, P. L., & Bolge, S. C. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1259167 · Cited by 9
Sugrue, D., van Haalen, H. G. M., Rai, S., & McEwan, P. C. (2018) · Value in Health · doi:10.1016/j.jval.2018.04.1805 · Cited by 7
Research works printed but not linked: 1
- Bergenheim K, Williams SA, Bergeson JG, Stern L, Sriprasert M. US cost-effectiveness of saxagliptin in type 2 diabetes mellitus. Am J Pharm Benefits. 2012;4(1):20–8.
Cited by
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2904 · Cited by 248
Yeo, S. C., Wang, H., Ang, G. Y., Lim, C. K., & Ooi, X. Y. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad137 · Cited by 105
Li, H., Dong, A., Li, N., Ma, Y., Zhang, S., Deng, Y., Chen, S., & Zhang, M. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s395512 · Cited by 30
“In addition, a recent study has shown that dapagliflozin increases the economic burden of kidney disease treatment in the United States.(9) For these reasons, there is an urgent need to find cost-effective ways to delay the progression of DKD.”
BackgroundRossing, P. R., Caramori, M. L., Chan, J. C. N., & Al., E. (2023) · KIDNEYS · doi:10.22141/2307-1257.11.4.2022.386 · Cited by 10
Metadata
- Authors
- Abegaz, T. M., Diaby, V., Sherbeny, F., & Ali, A. A.
- Affiliations
- Florida Agricultural and Mechanical University (US)
- Corresponding author
- Ali, Askal Ayalew
- Venue
- Clinical Drug Investigation
- Published
- 2022-05-25
- Volume
- 42
- Issue
- 6
- Pages
- 501-511
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W4281552441
- Cited by
- 15
- References
- 67
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 1 · 2023: 5 · 2022: 1
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- dapagliflozin, diabetic nephropathy, cost-effectiveness, SGLT2 inhibitors, ACE inhibitors, quality-adjusted life years, Medicare and Medicaid, adverse drug reactions, treatment costs
- MeSH terms
- Aged, Benzhydryl Compounds, Cost-Benefit Analysis, Diabetes Mellitus, Diabetic Nephropathies, Glucosides, Medicare, Humans, United States, Quality-Adjusted Life Years, Standard of Care, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.